Introduction
============

Cervical cancer is one of the most important reproductive health problems for adult women worldwide ([@b1-etm-0-0-7408]) and the second most common cancer among women worldwide ([@b2-etm-0-0-7408]). Approximately 500,000 newly diagnosed cases of cervical cancer are identified each year and at least 200,000 cases succumb to the disease ([@b3-etm-0-0-7408]). Cervical cancer incidence rates are high in developing countries, where more than 80% of the cervical cancer cases occur in the world ([@b4-etm-0-0-7408]). It is widely recognized that the leading cause of cervical cancer is persistent infection with specific types of the human papillomavirus ([@b5-etm-0-0-7408]). The complex process from normal tissue to cervical cancer involves going through mild dysplasia, moderate dysplasia, severe dysplasia, carcinoma *in situ*, and infiltrating carcinoma ([@b6-etm-0-0-7408]). This complex progression involves the abnormal expression of numerous oncogenes and tumor suppressor genes ([@b7-etm-0-0-7408]). The current primary treatment for cervical cancer is surgery, radiotherapy and chemotherapy ([@b8-etm-0-0-7408]). Although improvements have been made, there remain limitations associated with the current treatment options ([@b9-etm-0-0-7408]). Recurrent cervical cancer and metastasis occur frequently in patients with advanced cervical cancer ([@b10-etm-0-0-7408]). It is therefore important to investigate new and effective therapeutic targets for the treatment of cervical cancer.

MicroRNAs (miRNAs) are a class of small non-coding, single-stranded RNAs 19--25 nucleotides in length, found in eukaryotic cells. miRNAs can regulate post-transcriptional gene expression through mRNA degradation or translation inhibition of target mRNAs through the complete or partial binding in the 3′ untranslated regions (3′UTR) of target mRNAs ([@b11-etm-0-0-7408],[@b12-etm-0-0-7408]). Previous studies have demonstrated that miRNAs are involved in the development of various types of cancer ([@b13-etm-0-0-7408]--[@b16-etm-0-0-7408]). Abnormal expression of miRNAs is associated with the occurrence and development of cervical cancer through the regulation of target gene expression, which include oncogenes and tumor suppressor genes ([@b17-etm-0-0-7408]--[@b21-etm-0-0-7408]). MicroRNA-425-5p (miR-425-5p) was previously revealed to be upregulated in cervical cancer ([@b22-etm-0-0-7408]), however the cellular function of miR-425-5p in cervical cancer remains unknown. The aim of the current study was to investigate the cellular function of miR-425-5p and its underlying mechanism in cervical cancer.

Materials and methods
=====================

### Cell culture

Human cervical cancer cell lines HeLa, SiHa, C-33A and ME-180, as well as the human cervical epithelium cell line End1/E6E7 were purchased from American Type Culture Collection (Manassas, VA, USA). HeLa, SiHa and C-33A cells were grown in high glucose Dulbeco\'s modified Eagle medium and ME-180 cells were grown in RPMI 1640 medium (both Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), 1% streptomycin-penicillin solution and maintained at 37°C in a 5% CO~2~-humidified incubator. Cells were passaged every 2--3 days. End1/E6E7 cells were grown in Keratinocyte serum-free medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 0.1 ng/ml human recombinant epithelial growth factor, 0.05 mg/ml bovine pituitary extract (both Santa Cruz Biotechnology, Inc., Dallas, TX, USA), 1% streptomycin-penicillin solution and maintained at 37°C in a 5% CO~2~-humidified incubator.

### Dual-luciferase reporter assay

TargetScan bioinformatics software ([www.targetscan.org/vert_71](www.targetscan.org/vert_71)) was used to predict the putative target genes of miR-425--5. Apoptosis-inducing factor mitochondria-associated 1 (AIFM1) was identified as a potential target of miR-425-5p. The QuikChange Site-Directed Mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA, USA) was used, according to the manufacturer\'s protocol, to make a point mutation in the miR-425-5p binding domain on the 3′UTR of AIFM1. To confirm direct target binding, the wild-type (WT) 3′UTR AIFM1 or the mutant (MUT) 3′UTR AIFM1 were cloned into the dual-luciferase reporter vector pmiR-RB-REPORT™ (Guangzhou RiboBio Co., Ltd., Guangzhou, China). HeLa cells were co-transfected with 100 ng WT-AIFM1 or 100 ng MUT-AIFM1 and 50 nM miR-425-5p mimic (forward, 5′-AAUGACACGAUCACUCCCGUUGA-3′ and reverse, 5′-AACGGGAGUGAUCGUGUCAUUUU-3′) or 50 nM mimic control (forward, 5′-UUCUCCGAACGUGUCACGUTT-3′ and reverse, 5′-ACGUGACACGUUCGGAGAATT-3′) using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. MiR-425-5p mimic and mimic control were purchased from GenePharma Co., Ltd. (Shanghai, China). Following incubation for 48 h, luciferase activity was detected using a Dual-Luciferase^®^ Reporter assay system (Promega Corporation, Madison, WI, USA), according to the manufacturer\'s protocol. Firefly luciferase activity was normalized to *Renilla luciferase activity*.

### Cell transfection

HeLa cells were seeded into a 6-well plate at a density of 1×10^6^ cells/well and cultured at 37°C for 24 h. MiR-425-5p inhibitor and inhibitor control were obtained from GenePharma Co., Ltd. Cells were transfected with 100 nM miR-425-5p inhibitor (5′-AGGCGAAGGAUGACAAAGGGAA-3′), 100 nM inhibitor control (5′-CAGUACUUUUGUGUAGUACAA-3′), 10 µM control-siRNA (cat. no. 36869; Santa Cruz Biotechnology, Inc.), 10 µM AIFM1-siRNA (cat. no. 26926; OriGene Technologies, Inc., Rockville, MD, USA), miR-425-5p inhibitor + control-siRNA, or miR-425-5p inhibitor + AIFM1-siRNA using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. Following incubation for 48 h, transfection efficiency was measured.

### Cell proliferation assay

Cell viability was measured by MTT assay. Following a 48-h cell transfection, HeLa cells were seeded into 96-well plates at a density of 1×10^4^ cells/per well and cultured for 24 h. Following incubation, 20 ml MTT solution (0.5 mg/ml; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was added to each well and further incubated at 37°C for 4 h. Cell viability was determined by measuring the absorbance at a wavelength of 570 nm using a FLUOstar^®^ Omega Microplate Reader (BMG Labtech GmbH, Ortenberg, Germany).

### Flow cytometric analysis of apoptosis

Cell apoptosis was analyzed using the Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit (cat. no. 70-AP101-100; MultiSciences, Hangzhou, Zhejiang, China). Following a 48-h cell transfection, HeLa cells were harvested with 0.25% trypsin, washed with PBS and subsequently stained with 5 µl Annexin V-FITC and 5 µl PI for 30 min at room temperature without light. Early and late apoptotic cells were subsequently analyzed using a flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA), and data were analyzed using WinMDI software (version 2.5; Purdue University Cytometry Laboratories; [www.cyto.purdue.edu/flowcyt/software/Catalog.htm](www.cyto.purdue.edu/flowcyt/software/Catalog.htm)).

### Western blot analysis

Total protein was extracted from cells using radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Haimen, China), according to the manufacturer\'s protocol. Total protein was quantified using a bicinchoninic acid assay kit (Pierce; Thermo Fisher Scientific, Inc.) and 30 mg protein/lane was separated via SDS-PAGE on a 12% gel. The separated proteins were transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA) and blocked for 1 h at room temperature with 5% skimmed milk. The membranes were incubated with primary antibodies against AIFM1 (1:1,000; cat. no. BA3715-1; Boster Biological Technology, Pleasanton, CA, USA), DNA damage regulated autophagy modulator 1 (DRAM; 1:1,000; cat. no. 208160; Abcam, Cambridge, MA, USA), cytochrome c (1:1,000; cat. no. 11940), caspase-3 (1:1,000; cat. no. 9665), caspase-9 (1:1,000; cat. no. 9502) and β-actin (1:1,000; cat. no. 4970; all Cell Signaling Technology Inc., Danvers, MA, USA) overnight at 4°C. Following primary incubation, membranes were incubated with horseradish peroxidase-conjugated secondary antibody, anti-rabbit IgG (1:2,000; cat. no. 7074; Cell Signaling Technology, Inc.) for 2 h at room temperature. Protein bands were visualized using the enhanced chemiluminescence Western Blotting Detection kit (EMD Millipore).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from cells using TRIzol^®^ reagent (Invitrogen, Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. Total RNA was reverse transcribed into cDNA using the TaqMan^™^ MicroRNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. qPCR was subsequently performed using the SYBR^®^ Premix Ex Taq^™^ II kit (Takara Bio, Inc., Otsu, Japan). The following primer pairs were used for the qPCR: GAPDH forward, 5′CTTTGGTATCGTGGAAGGACTC3′ and reverse, 5′GTAGAGGCAGGGATGATGTTCT3′; and U6 forward, 5′GCTTCGGCAGCACATATACTAAAAT3′ and reverse, 5′CGCTTCACGAATTTGCGTGTCAT3′; miR-425-5p forward, 5′TGCGGAATGACACGATCACTCCCG3′ and reverse, 5′CCAGTGCAGGGTCCGAGGT3′; AIFM1 forward, 5′TTGAGAATGGTGGTGTGGCT3′ and reverse, 5′AGACTTCTTGGAGTACCTCCTGT3′; caspase-3 forward, 5′AGAACTGGACTGTGGCATTG3′ and reverse, 5′CACAAAGCGACTGGATGAAC3′; caspase-9 forward, 5′TGTTTCCGAGCGAGGGATTT3′ and reverse, 5′CGCAGGAAGGTTTTGGGGTA3′; DRAM forward, 5′AGACTCCATCTTTTCACCCAAA3′ and reverse, 5′GCTCTTCACCTTTCAAGCCTAA3′; cytochrome c forward, 5′TGCCACACTGTTGAAGCCGGT3′ and reverse, 5′GATCTGCACGCTCGTTTGCCT3′. The following thermocycling conditions were used for the qPCR: Initial denaturation at 95°C for 10 min; 35 cycles of 95°C for 15 sec and 55°C for 40 sec. The relative mRNA expression levels were quantified using the 2^−ΔΔCq^ method and normalized to the internal reference gene, U6 or GAPDH ([@b23-etm-0-0-7408]).

### Statistical analysis

Data are presented as the mean ± standard deviation of at least three independent experiments. All statistical analyses were performed using SPSS software (version 17.0; SPSS, Inc., Chicago. IL, USA). Student\'s t-test was performed for comparison analysis between two groups. One-way analysis of variance followed by Tukey\'s post hoc test was performed for analyze differences among multiple groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### miR-425-5p expression is upregulated in cervical cancer

In the current study, the expression level of miR-425-5p was determined by RT-qPCR in several human cervical cancer cell lines (HeLa, SiHa, C-33A and ME-180), as well as the human normal cervical epithelium cell line End1/E6E7. The miR-425-5p expression level was significantly increased in human cervical cancer cell lines compared with the normal cervical epithelium cell line ([Fig. 1](#f1-etm-0-0-7408){ref-type="fig"}). As the highest level of miR-425-5p expression was detected in HeLa cells, these were selected for all subsequent experiments.

### AIFM1 is a target gene of miR-425-5p

To further investigate the role of miR-425-5p in human cervical cancer, potential targets of miR-425-5p were examined. TargetScan bioinformatics software was used to identify AIFM1 as a putative target gene of miR-425-5p ([Fig. 2A](#f2-etm-0-0-7408){ref-type="fig"}). To confirm whether miR-425-5p directly regulates AIFM1 expression via interaction with the predicted binding sites, luciferase reporter assays were performed. Following co-transfection with miR-425-5p mimic, the luciferase reporter activity of WT-AIFM1 was significantly decreased compared with the luciferase reporter activity of MUT-AIFM1 ([Fig. 2B](#f2-etm-0-0-7408){ref-type="fig"}). The results suggest that AIFM1 is a direct target of miR-425-5p.

### Downregulation of miR-425-5p enhances AIFM1 expression in HeLa cells

To investigate the effect of miR-425-5p on cervical cancer, HeLa cells were transfected with miR-425-5p inhibitor, inhibitor control, AIFM1-siRNA, control-siRNA, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA, respectively. Following incubation for 48 h, transfection efficiency was measured. The current study demonstrated that the miR-425-5p inhibitor significantly decreased miR-425-5p expression in HeLa cells ([Fig. 3A](#f3-etm-0-0-7408){ref-type="fig"}). In addition, the mRNA and protein expression levels of AIFM1 were decreased in HeLa cells following transfection with AIFM1-siRNA ([Fig. 3B and C](#f3-etm-0-0-7408){ref-type="fig"}). Furthermore, the mRNA and protein expression levels of AIFM1 were increased following transfection with miR-425-5p inhibitor compared with the control group. However, AIFM1-siRNA reversed the effects observed with miR-425-5p inhibitor ([Fig. 3D and E](#f3-etm-0-0-7408){ref-type="fig"}).

### Downregulation of miR-425-5p inhibits HeLa cell viability

To investigate the cellular function of miR-425-5p in cervical cancer, the MTT assay was used to examine the viability of HeLa cells following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA. The current study demonstrated that the miR-425-5p inhibitor significantly decreased HeLa cell viability compared with the control group. However, AIFM1-siRNA significantly reversed the effect of miR-425-5p inhibitor on HeLa cell viability ([Fig. 4](#f4-etm-0-0-7408){ref-type="fig"}).

### Downregulation of miR-425-5p induces HeLa cell apoptosis

To further investigate the cellular function of miR-425-5p in cervical cancer, flow cytometry was used to examine cell apoptosis in HeLa cells following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA. The current study demonstrated that the miR-425-5p inhibitor significantly increased HeLa cell apoptosis compared with the control group. However, AIFM1-siRNA significantly reversed the effect of miR-425-5p inhibitor on HeLa cell apoptosis ([Fig. 5A and B](#f5-etm-0-0-7408){ref-type="fig"}).

### Downregulation of miR-425-5p upregulates the expression of cytochrome c, caspase-3, caspase-9 and DRAM in HeLa cells

To investigate the regulatory effect of miR-425-5p in cervical cancer, the expression of four pro-apoptotic genes, cytochrome c, caspase-3, caspase-9 and DRAM were examined in HeLa cells following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA ([Fig. 6](#f6-etm-0-0-7408){ref-type="fig"}). The current study demonstrated that the miR-425-5p inhibitor significantly upregulated both the protein and mRNA expression levels of all four pro-apoptotic genes analyzed, compared with the control group. However, the enhanced expression of these pro-apoptotic genes was significantly reversed by AIFM1 knockdown.

Discussion
==========

Increasing evidence suggests that miRNAs are involved in the development of various types of cancer ([@b13-etm-0-0-7408]--[@b16-etm-0-0-7408]). Previous reports have indicated that miRNAs serve a regulatory role in cell proliferation, differentiation, apoptosis, migration and metabolism ([@b12-etm-0-0-7408],[@b24-etm-0-0-7408],[@b25-etm-0-0-7408]). Studies have revealed that enhanced expression levels of miR-425-5p exist in different types of cancer, which suggest that miR-425-5p may have multiple functions in the development of cancer ([@b22-etm-0-0-7408],[@b26-etm-0-0-7408]). Studies previously demonstrated that miR-425-5p can promote invasion and metastasis in hepatocellular carcinoma, colorectal cancer and gastric cancer ([@b27-etm-0-0-7408]--[@b29-etm-0-0-7408]).

The aim of the current study was to investigate the cellular function of miR-425-5p and its underlying mechanism in cervical cancer. In the current study, the expression level of miR-425-5p was determined by RT-qPCR in several human cervical cancer cell lines including HeLa, SiHa, C-33A and ME-180, as well as the human normal cervical epithelium cell line End1/E6E7. miR-425-5p expression was significantly increased in human cervical cancer cell lines compared with the normal cervical epithelium cell line. In addition, HeLa cells expressed the highest level of miR-425-5p and were selected for all subsequent experiments.

To further investigate the role of miR-425-5p in human cervical cancer, potential targets of miR-425-5p were examined in HeLa cells using the TargetScan software. Bioinformatic analysis identified AIFM1 as a putative target gene of miR-425-5p and this was verified by dual-luciferase reporter assay. AIFM1, which is located in the mitochondrion intermembrane space, serves a role in the regulation of cell apoptosis ([@b30-etm-0-0-7408]--[@b33-etm-0-0-7408]).

The effect of miR-425-5p on cervical cancer cell viability and apoptosis was examined in HeLa cells. Downregulation of miR-425-5p significantly decreased cell viability and induced cell apoptosis, however, the inhibitory effect exerted by the miR-425-5p inhibitor was significantly reversed by AIFM1 knockdown. These results suggest that miR-425-5p inhibitor may function as a tumor suppressor in cervical cancer by enhancing the expression of AIFM1. AIFM1 is a phylogenetically conserved mitochondrial flavoprotein with NADH oxidation and potent apoptosis-inducing activity ([@b30-etm-0-0-7408]--[@b32-etm-0-0-7408]). AIFM1 induces mitochondria to release the apoptogenic proteins cytochrome c and caspase-9, thereby initiating apoptosis ([@b31-etm-0-0-7408],[@b33-etm-0-0-7408]). A previous study demonstrated that overexpression of AIFM1 induced apoptosis by promoting the transcription of caspase-3 and DRAM in hepatoma cells ([@b33-etm-0-0-7408]).

To investigate the underlying molecular mechanism of miR-425-5p in cervical cancer, the expression of pro-apoptotic genes including cytochrome c, caspase-3, caspase-9 and DRAM was examined in HeLa cells. The current study demonstrated that both the protein and mRNA expression levels of cytochrome c, caspase-3, caspase-9 and DRAM were significantly upregulated following transfection with miR-425-5p inhibitor. However, the enhanced expression of all four pro-apoptotic genes was significantly reversed by AIFM1 knockdown.

The present study investigated the cellular function of miR-425-5p and its underlying mechanism in cervical cancer, however *in vivo* studies and clinical trial data are required to validate the preliminary *in vitro* results obtained in the current study. Furthermore, the cellular function of AIFM1 alone in cervical cancer needs to be further investigated.

In conclusion, the current study demonstrated that miR-425-5p was upregulated in cervical cancer, and this may contribute to cervical cancer development by inhibiting AIFM1 expression. Furthermore, inhibition of miR-425-5p decreased cervical cancer cell viability and induced cell apoptosis. Therefore, the miR-425-5p/AIFM1 axis may serve a role in cervical cancer progression and this may be a promising therapeutic target for the treatment of patients.
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![miR-425-5p expression in human cervical cancer cell lines. The relative expression level of miR-425-5p was determined by reverse transcription-quantitative polymerase chain reaction in human cervical cancer cell lines HeLa, SiHa, C-33A and ME-180, and the normal cervical epithelium cell line End1/E6E7. Data are presented as the mean ± standard deviation. \*P\<0.05 and \*\*P\<0.01 vs. End1/E6E7. miR, microRNA.](etm-17-05-4032-g00){#f1-etm-0-0-7408}

![AIFM1 is a direct target gene of miR-425-5p. (A) TargetScan software was used to predict a binding site for miR-425-5p in the 3′UTR of AIFM1. (B) Luciferase activity of a dual-luciferase reporter vector containing wild-type 3′UTR-AIFM1 or a mutant 3′UTR-AIFM1. Data are presented as the mean ± standard deviation of three independent experiments. \*\*P\<0.01 vs. mimic control. AIFM1, apoptosis-inducing factor mitochondria-associated 1; UTR, untranslated region; miR, microRNA; WT, wild-type; MUT, mutant-type; WT-AIFM1, HeLa cells co-transfected with WT 3′UTR-AIFM1 and either mimic control or miR-425-5p; MUT-AIFM1, HeLa cells co-transfected with MUT 3′UTR-AIFM1 and either mimic control or miR-425-5p.](etm-17-05-4032-g01){#f2-etm-0-0-7408}

![miR-425-5p inhibitor enhances AIFM1 expression in HeLa cells. (A) The relative expression level of miR-425-5p was determined by reverse transcription-quantitative polymerase chain reaction in HeLa cells following transfection with miR-425-5p inhibitor and inhibitor control. The (B) mRNA and (C) protein expression level of AIFM1 was analyzed following transfection with AIFM1-siRNA or control-siRNA. The (D) mRNA and (E) protein expression level of AIFM1 was analyzed following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA. Data are presented as the mean ± standard deviation. \*\*P\<0.01 vs. control group; ^\#\#^P\<0.01 vs. inhibitor group. AIFM1, apoptosis-inducing factor mitochondria-associated 1; miR, microRNA; siRNA, small interfering RNA; control, untransfected HeLa cells; inhibitor control, HeLa cells transfected with inhibitor control; inhibitor, HeLa cells transfected with miR-425-5p inhibitor; control-siRNA, HeLa cells transfected with control siRNA; siRNA, HeLa cells transfected with AIFM1-siRNA; inhibitor + control-siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and control siRNA; inhibitor + siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and AIFM1-siRNA.](etm-17-05-4032-g02){#f3-etm-0-0-7408}

![miR-425-5p inhibitor suppresses HeLa cell viability. MTT assay was used to examine cell viability of HeLa cells following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA. Data are presented as the mean ± standard deviation. \*\*P\<0.01 vs. control group; ^\#\#^P\<0.01 vs. inhibitor group. siRNA, small interfering RNA; control, untransfected HeLa cells; inhibitor control, HeLa cells transfected with inhibitor control; inhibitor, HeLa cells transfected with miR-425-5p inhibitor; inhibitor + control-siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and control siRNA; inhibitor + siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and AIFM1-siRNA.](etm-17-05-4032-g03){#f4-etm-0-0-7408}

![miR-425-5p inhibitor induces HeLa cell apoptosis. (A) Early apoptosis (Q2) and late apoptosis (Q4) was detected by flow cytometry in HeLa cells following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA. (B) The effect of miR-425-5p knockdown on HeLa cell apoptosis was examined. Data are presented as the mean ± standard deviation. \*\*P\<0.01 vs. control group; ^\#\#^P\<0.01 vs. inhibitor group. siRNA, small interfering RNA; FITC, fluorescein isothiocyanate; control, untransfected HeLa cells; inhibitor control, HeLa cells transfected with inhibitor control; inhibitor, HeLa cells transfected with miR-425-5p inhibitor; inhibitor + control-siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and control siRNA; inhibitor + siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and AIFM1-siRNA; PI, propidium iodide.](etm-17-05-4032-g04){#f5-etm-0-0-7408}

![miR-425-5p inhibitor upregulates pro-apoptotic gene expression in HeLa cells. (A) The protein expression levels of cytochrome c, caspase-3, caspase-9 and DRAM were determined by western blot analysis in HeLa cells following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA. The mRNA expression levels of (B) cytochrome c, (C) caspase-3, (D) caspase-9 and (E) DRAM were determined by reverse transcription-quantitative polymerase chain reaction in HeLa cells following transfection with miR-425-5p inhibitor, inhibitor control, miR-425-5p inhibitor + AIFM1-siRNA or miR-425-5p inhibitor + control-siRNA. Data are presented as the mean ± standard deviation. \*P\<0.05 and \*\*P\<0.01 vs. control group; ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. inhibitor group. DRAM, DNA damage regulated autophagy modulator 1; siRNA, small interfering RNA; control, untransfected HeLa cells; inhibitor control, HeLa cells transfected with inhibitor control; inhibitor, HeLa cells transfected with miR-425-5p inhibitor; inhibitor + control-siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and control siRNA; inhibitor + siRNA, HeLa cells co-transfected with miR-425-5p inhibitor and AIFM1-siRNA.](etm-17-05-4032-g05){#f6-etm-0-0-7408}
